Talk:Rotigotine
| This is the talk page for discussing improvements to the Rotigotine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Rotigotine.
|
The original creator of NEUPRO PATCH edit
The original creators of the neupro patch was Aderis Pharmaceuticals represented by Gevork Minaskanian, Ph.D., Noel J. Cusack, Ph.D., James V. Peck, Pharm D.,William S. Wheeler, M.D., and Kenneth L. Rice Jr., M.B.A., J.D. Their creation was sold to schwartz pharma that was later bought by UCB. —Preceding unsigned comment added by 204.8.204.116 (talk) 01:18, 12 October 2007 (UTC)
Binding profile clarification needed edit
The receptor binding profile lists a certain D2 affinity but it needs to be clarified as separate affinities for: D2S, D2L, and D2VL. The functions of those different D2 receptors are dramatically different than each other. I would assume that the given D2 affinity specified is for D2L, but this should be specified, and the D2S and D2VL affinities are very important information. 162.89.0.47 (talk) —Preceding undated comment added 17:14, 11 April 2017 (UTC)